Prelude Capital Management, LLC Tg Therapeutics, Inc. Call Options Transaction History

Prelude Capital Management, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$5.01 - $11.83 $501 - $1,183	-100 Reduced 0.48%	20,800 $246,000
Q2 2022 Aug 15, 2022	SELL	$3.74 - $10.66 $748 - $2,132	-200 Reduced 0.95%	20,900 $89,000
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $13,277 - $34,765	-1,700 Reduced 7.46%	21,100 $201,000
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $76,000 - $177,550	5,000 Added 28.09%	22,800 $433,000
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $387,684 - $720,010	17,800 New	17,800 $592,000
Q3 2020 Nov 16, 2020	SELL	$18.49 - $27.24 $55,469 - $81,720	-3,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.9 - $21.84 $26,700 - $65,520	3,000 New	3,000 $58,000
Q1 2020 May 15, 2020	SELL	$7.14 - $15.99 $146,370 - $327,795	-20,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $102,000 - $224,000	20,000 Added 4000.0%	20,500 $228,000
Q3 2019 Nov 14, 2019	SELL	$5.38 - $8.99 $2,152 - $3,596	-400 Reduced 44.44%	500 $3,000
Q2 2019 Aug 14, 2019	SELL	$6.27 - $8.65 $627 - $865	-100 Reduced 10.0%	900 $8,000
Q1 2019 May 15, 2019	BUY	$4.02 - $8.04 $4,019 - $8,039	1,000 New	1,000 $8,000

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.